Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
- 31 January 2013
- journal article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 71 (3), 663-670
- https://doi.org/10.1007/s00280-012-2055-z
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsThe New England Journal of Medicine, 2011
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010
- Survival and Prognostic Factor Analysis in Patients With Metastatic Pancreatic Endocrine CarcinomasPancreas, 2009
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomasCancer, 2008
- Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine TumorsJournal of Clinical Oncology, 2006
- Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281Journal of Clinical Oncology, 2005
- The 3′ → 5′ Exonuclease of T4 DNA Polymerase Removes Premutagenic Alkyl Mispairs and Contributes to Futile Cycling atO 6-Methylguanine LesionsPublished by Elsevier BV ,2001
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsCancer Treatment Reviews, 1997
- p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells.Gut, 1996